MeSH term
Frequency | Condition_Probility | Animals | 34 | 0.0 |
Cell Differentiation | 2 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/chemistry/genetics/*metabolism | 2 | 50.0 |
*DNA Methylation | 26 | 4.0 |
Humans | 76 | 0.0 |
Mice | 29 | 0.0 |
NIH 3T3 Cells | 3 | 1.0 |
Protein Binding | 7 | 0.0 |
Protein Structure, Tertiary | 6 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 58 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 36 | 0.0 |
Carcinoma, Hepatocellular/*genetics | 2 | 2.0 |
Cell Line | 20 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/*genetics/metabolism | 3 | 50.0 |
DNA Primers | 6 | 0.0 |
Liver Neoplasms/*genetics | 2 | 1.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Protein Conformation | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 15 | 0.0 |
Transfection | 10 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
*CpG Islands | 3 | 3.0 |
DNA Methylation | 29 | 4.0 |
DNA, Neoplasm/metabolism | 3 | 2.0 |
Gene Deletion | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 5 | 0.0 |
*Genes, Tumor Suppressor | 5 | 0.0 |
Promoter Regions (Genetics) | 8 | 0.0 |
RNA, Neoplasm/biosynthesis | 2 | 1.0 |
Transcription, Genetic | 6 | 0.0 |
Tumor Cells, Cultured | 14 | 0.0 |
*Tumor Suppressor Proteins | 3 | 0.0 |
Catalysis | 2 | 0.0 |
Cells, Cultured | 3 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/*metabolism | 2 | 15.0 |
Gene Silencing | 3 | 0.0 |
Kinetics | 4 | 0.0 |
Amino Acid Sequence | 8 | 0.0 |
COS Cells | 5 | 0.0 |
Cercopithecus aethiops | 3 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/genetics/*metabolism | 8 | 50.0 |
Female | 25 | 0.0 |
Gene Expression | 5 | 0.0 |
*Genomic Imprinting | 4 | 1.0 |
Male | 19 | 0.0 |
Mice, Knockout | 4 | 0.0 |
Molecular Sequence Data | 10 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/*physiology | 3 | 60.0 |
*Gene Silencing | 5 | 2.0 |
Gene Targeting | 2 | 0.0 |
Adult | 8 | 0.0 |
Aged | 9 | 0.0 |
Aged, 80 and over | 5 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/*genetics | 15 | 53.0 |
Genotype | 2 | 0.0 |
Middle Aged | 8 | 0.0 |
Prognosis | 2 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Immunohistochemistry | 2 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Base Sequence | 8 | 0.0 |
Cell Line, Transformed | 4 | 0.0 |
CpG Islands | 10 | 3.0 |
In Vitro | 2 | 0.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Flow Cytometry | 4 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Gene Expression Regulation | 3 | 0.0 |
Immunologic Deficiency Syndromes/*genetics | 3 | 10.0 |
*Mutation | 5 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Phenotype | 3 | 0.0 |
Syndrome | 5 | 0.0 |
Alternative Splicing | 3 | 0.0 |
Binding Sites | 3 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
Models, Genetic | 6 | 0.0 |
Blotting, Western | 4 | 0.0 |
Microscopy, Fluorescence | 2 | 0.0 |
CpG Islands/genetics | 4 | 2.0 |
DNA (Cytosine-5-)-Methyltransferase/*biosynthesis/genetics | 3 | 75.0 |
Gene Expression Regulation, Neoplastic | 5 | 0.0 |
Mice, Nude | 2 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
DNA/genetics/metabolism | 2 | 0.0 |
Glutathione Transferase/genetics/metabolism | 2 | 1.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
*Chromosome Aberrations | 3 | 0.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Cell Line, Tumor | 8 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/genetics/metabolism | 4 | 44.0 |
Gene Therapy/methods | 2 | 2.0 |
Histones/metabolism | 5 | 2.0 |
Methylation | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 4 | 0.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Gene Expression Regulation, Enzymologic | 2 | 0.0 |
DNA, Neoplasm/genetics | 3 | 0.0 |
Oligonucleotides, Antisense/pharmacology | 2 | 0.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Centromere | 2 | 2.0 |
Mammals | 2 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
Mutation | 4 | 0.0 |
Child | 2 | 0.0 |
Child, Preschool | 3 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/genetics | 7 | 70.0 |
Infant | 2 | 0.0 |
Face/*abnormalities | 4 | 10.0 |
Case-Control Studies | 3 | 0.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Colorectal Neoplasms/enzymology/*genetics | 2 | 12.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Fluorescent Antibody Technique | 4 | 0.0 |
Hela Cells | 5 | 0.0 |
Interphase | 2 | 1.0 |
Macromolecular Substances | 2 | 0.0 |
Mitosis | 2 | 0.0 |
Precipitin Tests | 5 | 0.0 |
Protein Transport | 2 | 0.0 |
Xenopus | 2 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Histone Deacetylases/genetics/*metabolism | 2 | 4.0 |
Methyltransferases/metabolism | 3 | 9.0 |
Spodoptera/cytology | 2 | 4.0 |
Chromatin/*metabolism | 2 | 1.0 |
Face/abnormalities | 2 | 3.0 |
Time Factors | 2 | 0.0 |
*Dosage Compensation (Genetics) | 2 | 1.0 |
Azacitidine/*analogs & derivatives/pharmacology | 2 | 2.0 |
RNA, Messenger/metabolism | 4 | 0.0 |
Sulfites/pharmacology | 2 | 6.0 |
*Transcription, Genetic | 3 | 0.0 |
Cell Division/genetics | 2 | 0.0 |
Comparative Study | 5 | 0.0 |
Genome, Human | 2 | 0.0 |
DNA/*metabolism | 2 | 0.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Signal Transduction | 3 | 0.0 |
Alleles | 3 | 0.0 |
DNA (Cytosine-5-)-Methyltransferase/deficiency/genetics | 2 | 100.0 |
Epigenesis, Genetic/*genetics | 2 | 28.0 |
Cell Division | 2 | 0.0 |
Chromatin/metabolism | 2 | 0.0 |
Neoplasms/*genetics | 2 | 0.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Hydroxamic Acids/pharmacology | 2 | 1.0 |
DNA (Cytosine-5-)-Methyltransferase/metabolism | 2 | 25.0 |
